ASCO: BeiGene, Novartis Herald Global PD-1 Contender In ESCC

Filings Approaching

 
• By Dexter Jie Yan and John Davis

The Chinese biotech is set to extend the reach of its PD-1 candidate to the global market with a second major clinical win and following an earlier major deal with Novartis.

Magnifying lens over background with text Immuno-oncology, with the blurred lights visible in the background. 3D rendering.
More Progress For BeiGene's Immuno-Oncology Pipeline • Source: Shutterstock

More from ASCO

More from Conferences